var data={"title":"Famotidine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Famotidine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6179?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=famotidine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Famotidine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=famotidine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Famotidine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169927\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Acid Reducer Maximum Strength [OTC];</li>\n      <li>Acid Reducer [OTC];</li>\n      <li>Heartburn Relief Max St [OTC];</li>\n      <li>Heartburn Relief [OTC];</li>\n      <li>Pepcid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169928\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Acid Control;</li>\n      <li>Apo-Famotidine;</li>\n      <li>Famotidine Omega;</li>\n      <li>Maximum Strength Pepcid AC;</li>\n      <li>Mylan-Famotidine;</li>\n      <li>Pepcid AC;</li>\n      <li>Pepcid Complete;</li>\n      <li>Peptic guard;</li>\n      <li>Teva-Famotidine;</li>\n      <li>Ulcidine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169978\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Histamine H<sub>2</sub> Antagonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169931\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Duodenal ulcer:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 20 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Acute therapy: 40 mg once daily at bedtime (or 20 mg twice daily) for 4 to 8 weeks; maintenance therapy: 20 mg once daily at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastric ulcer:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 20 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Acute therapy: 40 mg/day at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>GERD:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Esophagitis and accompanying symptoms due to GERD: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 20 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 20 mg or 40 mg twice daily for up to 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment of GERD (short-term):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 20 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 20 mg twice daily for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heartburn:</b> OTC labeling: Oral: 10 to 20 mg every 12 hours (maximum dose: 40 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pathological hypersecretory conditions:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Initial: 20 mg every 6 hours (higher initial dose may be required); may adjust dose based on patient response up to 160 mg every 6 hours has been used). <b>Note:</b> Proton pump inhibitors (PPIs) are preferred for hypersecretory conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Reducing gastrointestinal risks of NSAIDs and antiplatelet therapies (off-label use):</b> Oral: 40 mg twice daily (Abraham 2010; Lanza 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Refractory urticaria, treatment (off-label use):</b> Oral: 20 mg twice daily (Bernstein 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Stress ulcer prophylaxis in critically-ill patients (off-label use):</b> Oral, IV, or nasogastric (NG) tube: 20 mg twice daily (ASHP 1999; Baghaie 1995); <b>Note:</b> Intended for patients with associated risk factors (eg, coagulopathy, mechanical ventilation for &gt;48 hours, sepsis/septic shock); discontinue use once risk factors have resolved (Rhodes 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169952\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=famotidine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Famotidine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>GERD:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment of GERD (short-term): </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 1 to &lt;3 months: 0.5 mg/kg/dose once daily for up to 8 weeks; if not effective, may increase to 1 mg/kg once daily (Orenstein 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;3 months to &lt; 1 year: 0.5 mg/kg/dose twice daily for up to 8 weeks; if not effective, may increase to 1 mg/kg twice daily (Orenstein 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;1 year to Adolescents &le;16 years: 0.5 mg/kg/dose twice daily (maximum dose: 40 mg twice daily); doses up to 1 mg/kg/dose twice daily have been used</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heartburn:</b> OTC labeling: Oral: Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pathological hypersecretory conditions:</b> Oral: Adolescents &ge;17 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peptic ulcer:</b> Children &ge;1 year to Adolescents &le;16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 0.5 mg/kg/day at bedtime or divided twice daily (maximum dose: 40 mg/day); doses up to 1 mg/kg/day have been used</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 0.25 mg/kg every 12 hours (maximum dose: 40 mg/day); doses up to 0.5 mg/kg every 12 hours have been used</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169932\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169933\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;50 mL/minute: Administer 50% of dose <b>or</b> increase the dosing interval to every 36 to 48 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: There are no specific dosage adjustments provided in the manufacturer's labeling; however, decreased doses or extended dosing intervals are recommended in patients with moderate to severe renal impairment; some have suggested the following (Aronoff 2007): <b>Note:</b> Renally adjusted dose recommendations are based on doses of 0.5 to 1 mg/kg/day divided every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: 0.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 0.25 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 0.125 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent hemodialysis: 0.125 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis (PD): 0.125 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous renal replacement therapy (CRRT): 0.5 mg/kg/dose every 24 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50049610\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169901\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg (50 mL); 20 mg/2 mL (2 mL); 40 mg/4 mL (4 mL); 200 mg/20 mL (20 mL); 500 mg/50 mL (50 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg/2 mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pepcid: 40 mg/5 mL (50 mL) [contains methylparaben sodium, propylparaben sodium, sodium benzoate; cherry banana mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 40 mg/5 mL (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acid Reducer: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acid Reducer Maximum Strength: 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Heartburn Relief: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Heartburn Relief Max St: 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pepcid: 20 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pepcid: 20 mg [contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pepcid: 40 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pepcid: 40 mg [contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 20 mg, 40 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169887\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169904\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Inject over at least 2 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution for infusion: Administer over 15 to 30 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May administer with antacids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Suspension: Shake vigorously before use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet (OTC): Do not chew. To prevent symptoms, administer 10 to 60 minutes before eating food or drinking beverages known to cause heartburn.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169903\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Duodenal ulcer:</b> Short-term treatment of active duodenal ulcer and maintenance therapy after healing of active ulcer.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastric ulcer:</b> Short-term treatment of active benign gastric ulcer.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastroesophageal reflux disease: </b> Short-term treatment of gastroesophageal reflux disease (GERD) and esophagitis due to GERD, including erosive or ulcerative disease diagnosed by endoscopy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pathological hypersecretory conditions:</b> Treatment of pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome, multiple endocrine adenomas).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heartburn (OTC only):</b> Relief of heartburn, acid indigestion, and sour stomach.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725590\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Gastritis (symptomatic relief); Reducing gastrointestinal risks of NSAIDs and antiplatelet therapies; Refractory urticaria, treatment:; Stress ulcer prophylaxis in critically-ill patients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7305905\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Famotidine may be confused with FLUoxetine, furosemide</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169894\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Agitation (&lt;1 year of age: &le;14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (&lt;1 year of age: &le;14%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (5%), dizziness (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (2%), constipation (1%), necrotizing enterocolitis (very low birth weight neonates; Guillet 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal distress, acne vulgaris, agranulocytosis, alopecia, anaphylaxis, angioedema, anorexia, anxiety, arthralgia, atrioventricular block, bronchospasm, cardiac arrhythmia, cholestatic jaundice, confusion, conjunctival injection, decreased libido, depression, drowsiness, dysgeusia, facial edema, fatigue, fever, flushing, hallucination, hepatitis, hypersensitivity reaction, increased liver enzymes, injection site reaction, insomnia, interstitial pneumonitis, leukopenia, muscle cramps, nausea, palpitations, pancytopenia, paresthesia, prolonged Q-T interval on ECG, pruritus, rhabdomyolysis, seizure, skin rash, Stevens-Johnson syndrome, thrombocytopenia, tinnitus, torsades de pointes, toxic epidermal necrolysis, urticaria, weakness, xeroderma, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169907\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to famotidine, other H<sub>2</sub> antagonists, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC labeling: When used for self-medication (OTC), do not use if trouble or pain when swallowing food, vomiting with blood, or bloody or black stools; allergic to other acid reducers; renal impairment; coadministration with other acid reducers.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169891\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects.</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; ECG changes: Prolonged QT interval has been reported in patients with renal dysfunction. The FDA has received reports of torsades de pointes occurring with famotidine (Poluzzi 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vitamin B<sub>12</sub> deficiency: Prolonged treatment (&ge;2 years) may lead to vitamin B<sub>12</sub> malabsorption and subsequent vitamin B<sub>12</sub> deficiency. The magnitude of the deficiency is dose-related and the association is stronger in females and those younger in age (&lt;30 years); prevalence is decreased after discontinuation of therapy (Lam 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with moderate to severe renal impairment (CrCl &lt;50 mL/minute); dosage adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use of gastric acid inhibitors, including proton pump inhibitors and H<sub>2</sub> blockers, has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia in pediatric patients (Canani 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol and/or sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol and/or benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; OTC labeling: When used for self-medication (OTC), notify health care provider before use if any of the following are present: Frequent chest pain; frequent wheezing particularly with heartburn; nausea/vomiting; unexplained weight loss; stomach pain; heartburn &gt;3 months; heartburn with light-headedness, sweating, or dizziness; chest pain or shoulder pain with shortness of breath; sweating; pain that spreads to arms, neck, or shoulders; light-headedness. Discontinue use and notify health care provider if heartburn continues or worsens, or if use is required &gt;14 days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299312\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OCT2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169896\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8436&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Acalabrutinib.  Management: To minimize the potential for a significant interaction, separate administration of these agents by giving acalabrutinib 2 hours before ingestion of a histamine-2 receptor antagonist.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Atazanavir.  Management: Specific dose limitations and administration guidelines exist; consult full interaction monograph or atazanavir prescribing information.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Bosutinib.  Management: Administer histamine H2 receptor antagonists more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May increase the serum concentration of OCT2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefditoren: Histamine H2 Receptor Antagonists may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with H2-antagonists and antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefpodoxime: Histamine H2 Receptor Antagonists may decrease the absorption of Cefpodoxime. Separate oral doses by at least 2 hours. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefuroxime: Histamine H2 Receptor Antagonists may decrease the absorption of Cefuroxime. Separate oral doses by at least 2 hours. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cysteamine (Systemic): Histamine H2 Receptor Antagonists may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Dabrafenib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: Histamine H2 Receptor Antagonists may decrease the absorption of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of H2-antagonists if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delavirdine: Histamine H2 Receptor Antagonists may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with H2-antagonists should be avoided in patients who are being treated with delavirdine.  The clinical significance of short-term H2-antagonist therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexmethylphenidate: Histamine H2 Receptor Antagonists may increase the absorption of Dexmethylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Erlotinib.  Management: Avoid H2-antagonists in patients receiving erlotinib when possible.  If concomitant treatment cannot be avoided, erlotinib should be dosed once daily, 10 hours after and at least 2 hours before H2-antagonist dosing.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Fosamprenavir. Cimetidine may also inhibit the metabolism of the active metabolite amprenavir, making its effects on fosamprenavir/amprenavir concentrations difficult to predict. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gefitinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Gefitinib.  Management: Administer gefitinib at least 6 hours before or after administration of a histamine H2-antagonist, and closely monitor clinical response to gefitinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indinavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: Histamine H2 Receptor Antagonists may decrease the absorption of Iron Salts. <b> Exceptions: </b>Ferric Carboxymaltose; Ferric Citrate; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: Histamine H2 Receptor Antagonists may decrease the serum concentration of Itraconazole.  Management: When this combination is used, the itraconazole should be administered with a non-diet cola beverage (8 ounces). Itraconazole oral suspension may be less sensitive to this interaction.  Monitor patient response to itraconazole closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): Histamine H2 Receptor Antagonists may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any H2-receptor antagonist.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Ledipasvir. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mesalamine: Histamine H2 Receptor Antagonists may diminish the therapeutic effect of Mesalamine. Histamine H2-Antagonist-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose histamine H2-receptor antagonists with sustained-release mesalamine products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Histamine H2 Receptor Antagonists may increase the absorption of Methylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): Histamine H2 Receptor Antagonists may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be impaired by H2-antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Nelfinavir. Concentrations of the active M8 metabolite may also be reduced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Neratinib. Specifically, histamine H2 receptor antagonists may reduce neratinib absorption. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Nilotinib.  Management: The nilotinib dose should be given 10 hours after or 2 hours before the H2 receptor antagonist in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: Histamine H2 Receptor Antagonists may decrease the serum concentration of PAZOPanib.  Management: Avoid the use of histamine H2-antagonists in combination with pazopanib.  Strategies to minimize the expected interaction between these agents (eg, dose separation) have not been investigated.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: Histamine H2 Receptor Antagonists may decrease the serum concentration of Posaconazole.  Management: Avoid concurrent use of oral suspension with H2-antagonists whenever possible. Monitor patients closely for decreased antifungal effects if this combination is used. Delayed-release posaconazole tablets may be less likely to interact.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: Histamine H2 Receptor Antagonists may decrease the serum concentration of Rilpivirine.  Management: Administer histamine H2 receptor antagonists at least 12 hours before or 4 hours after rilpivirine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Risedronate: Histamine H2 Receptor Antagonists may increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: Histamine H2 Receptor Antagonists may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Histamine H2 Receptor Antagonists may diminish the diagnostic effect of Secretin. Specifically, use of H2-Antagonists may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma.  Management: Avoid concomitant use of histamine H2-antagonists (H2RAs) and secretin. Discontinue H2RAs at least 2 days prior to secretin administration.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varenicline: Histamine H2 Receptor Antagonists may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concomitant use of cimetidine or other H2-antagonists, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Velpatasvir. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169924\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Prolonged treatment (&ge;2 years) may lead to malabsorption of dietary vitamin B<sub>12</sub> and subsequent vitamin B<sub>12</sub> deficiency (Lam 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169898\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169910\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Famotidine crosses the placenta (Wang 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Due to pregnancy-induced physiologic changes, renal clearance of famotidine may be increased (Wang 2011). Histamine H<sub>2</sub> antagonists have been evaluated for the treatment of gastroesophageal reflux disease (GERD) during pregnancy. Agents other than famotidine may be preferred for initial therapy (Richter 2005; van der Woude 2014). Histamine H<sub>2</sub> antagonists may be used for aspiration prophylaxis prior to cesarean delivery (ASA 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169911\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Famotidine is present in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of famotidine is 2.2% when calculated using the highest breast milk concentration located and compared to an infant therapeutic dose of 0.5 mg/kg/day.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The RID of famotidine was calculated using a milk concentration of 0.072 mcg/mL, providing an estimated daily infant dose via breast milk of 0.011 mg/kg/day. This milk concentration was obtained following maternal administration of a single dose of famotidine 40 mg orally (Courtney 1988).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. When treatment with a histamine H<sub>2</sub> antagonist is needed, famotidine is one of the preferred agents due to its lower concentrations in breast milk (Richter 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50442698\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC, gastric pH, occult blood with GI bleeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169890\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Competitive inhibition of histamine at H<sub>2</sub> receptors of the gastric parietal cells, which inhibits gastric acid secretion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169906\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Antisecretory effect: Oral: Within 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: Antisecretory effect: Oral: Within 1 to 3 hours (dose-dependent); IV: Within 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Antisecretory effect: IV, Oral: 10 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Incompletely absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: 0 to 3 months of age: 1.4 &plusmn; 0.4 L/kg to 1.8 &plusmn; 0.3 L/kg; &gt;3 to 12 months: 2.3 &plusmn; 0.7 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &lt;11 years of age: 2.07 &plusmn; 1.49 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents 11 to 15 years of age: 1.5 &plusmn; 0.4 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 1.3 &plusmn; 0.2 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 15% to 20%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: 30% to 35%; minimal first-pass metabolism; forms one metabolite (S-oxide)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: 40% to 45%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: 0 to 3 months of age: 8.1 &plusmn; 3.5 hours to 10.5 &plusmn; 5.4 hours; &gt;3 to 12 months: 4.5 &plusmn; 1.1 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &lt;11 years of age: 3.38 &plusmn; 2.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents 11 to 15 years of age: 2.3 &plusmn; 0.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 2.5 to 3.5 hours; prolonged with renal impairment; Oliguria: &gt;20 hours; Anuria: 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Oral: ~1 to 3 hours; orally disintegrating tablet: 2.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (25% to 30% [oral], 65% to 70% [IV] as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: 0 to 3 months of age: 0.13 to 0.21 &plusmn; 0.06 L/hour/kg; &gt;3 to 12 months: 0.49 &plusmn; 0.17 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &lt;11 years of age of age: 0.54 &plusmn; 0.34 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents 11 to 15 years of age: 0.48 &plusmn; 0.14 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 0.39 &plusmn; 0.14 L/hour/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169909\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Famotidine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/2 mL (2 mL): $0.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/4 mL (4 mL): $2.14</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/20 mL (20 mL): $8.73</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Famotidine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/5 mL (50 mL): $176.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Pepcid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/5 mL (50 mL): $235.52</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Famotidine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $1.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $173.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (100): $401.28</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Pepcid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $363.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $645.26</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169913\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acifam (JO);</li>\n      <li>Androtin (MX);</li>\n      <li>Antiflam (UY);</li>\n      <li>Antodine (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Aulzadin (HK);</li>\n      <li>Ausfam (AU);</li>\n      <li>Bestidine (KR);</li>\n      <li>Corocyd (ID);</li>\n      <li>Denufam (ID);</li>\n      <li>Durater (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Facid (ID, IN);</li>\n      <li>Facidex (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Fadin (TW, VN);</li>\n      <li>Fadine (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Fadul (DE);</li>\n      <li>Famagen (KR);</li>\n      <li>Famo (BD, IL);</li>\n      <li>Famoc (SG);</li>\n      <li>Famocid (AE, BF, BJ, CI, ET, GH, GM, GN, IN, KE, KW, LR, MA, ML, MR, MU, MW, NE, NG, QA, SA, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Famodar (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Famodil (IT);</li>\n      <li>Famodin (RO);</li>\n      <li>Famodine (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, MY, OM, PK, QA, SA, SY, YE);</li>\n      <li>Famogal (CO);</li>\n      <li>Famogard (RU);</li>\n      <li>Famohexal (AU);</li>\n      <li>Famonerton (DE);</li>\n      <li>Famopsin (CY, TR);</li>\n      <li>Famosan (CZ, EE, HR);</li>\n      <li>Famosia (TH);</li>\n      <li>Famotaz (LK);</li>\n      <li>Famotec (AE, QA);</li>\n      <li>Famotid (BR);</li>\n      <li>Famotin (SG);</li>\n      <li>Famowal (IN);</li>\n      <li>Famox (BR, NZ, TW);</li>\n      <li>Famozol (UA);</li>\n      <li>Faradin (HK);</li>\n      <li>Farotin (KR);</li>\n      <li>Ferotine (KR);</li>\n      <li>Fibonel (CL);</li>\n      <li>Fudone (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Fuweidin (TW);</li>\n      <li>Gasafe (TW);</li>\n      <li>Gasmodin (VN);</li>\n      <li>Gaster (CN, JP, KR, TW);</li>\n      <li>Gastren (PY);</li>\n      <li>Gastridin (IT);</li>\n      <li>Gastril (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Gastrium (PY);</li>\n      <li>Gastro (IL);</li>\n      <li>Gastrodomina (BF, BJ, CI, ET, GH, GM, GN, HU, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Gastrum (CO);</li>\n      <li>H2 Bloc (PH);</li>\n      <li>Hastrotyd (UA);</li>\n      <li>Hista-Bloc (PH);</li>\n      <li>Interfam (HK);</li>\n      <li>Keamotin (HK);</li>\n      <li>Kimodin (TW);</li>\n      <li>Kvamatel (UA);</li>\n      <li>Logos (ZA);</li>\n      <li>Ludex (MX);</li>\n      <li>Modin (PH);</li>\n      <li>Motiax (IT);</li>\n      <li>Motidin (HU);</li>\n      <li>Navatac (BD);</li>\n      <li>Nenvofam (VN);</li>\n      <li>Nulcerin (ES);</li>\n      <li>Nulcex (ES);</li>\n      <li>Pamacid (AU);</li>\n      <li>Pepcid (BB, BM, BS, BZ, ES, GB, GY, IE, JM, SE, SR, TT);</li>\n      <li>Pepcid AC (CH);</li>\n      <li>Pepcidac (FR);</li>\n      <li>Pepcidin (DK, FI, JO, NL, QA, SE);</li>\n      <li>Pepcidina (PT);</li>\n      <li>Pepcidine (AT, BE, CH, LU, MX, NZ, PE, VN);</li>\n      <li>Pepdif (TR);</li>\n      <li>Pepdine (BF, BJ, CI, ET, FR, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Pepfamin (TH);</li>\n      <li>Peptifam (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Peptoci (TH);</li>\n      <li>Pepzan (AU, MY, NZ);</li>\n      <li>Pharmotidine (PH);</li>\n      <li>Quamatel (HU, LV);</li>\n      <li>Quamtel (BM, BS, BZ, GY, JM, SR, TT);</li>\n      <li>Rogasti (IL);</li>\n      <li>Sedanium-R (GR);</li>\n      <li>Snow (BD);</li>\n      <li>Stadin (KR);</li>\n      <li>Stomax (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Supertidine (TW);</li>\n      <li>Tarpan (PY);</li>\n      <li>Tismafam (ID);</li>\n      <li>Topcid (IN);</li>\n      <li>Ulcatif (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Ulcelac (AR);</li>\n      <li>Ulcenol (VE);</li>\n      <li>Ulceran (AE, BG, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SG, SY, TR, YE);</li>\n      <li>Ulfadin (CO);</li>\n      <li>Ulfagel (EC);</li>\n      <li>Ulfamid (HR, HU, PL);</li>\n      <li>Ulmo (ID);</li>\n      <li>Vesmo-20 (TH);</li>\n      <li>Voker (MY);</li>\n      <li>Weimok (TW);</li>\n      <li>Winiful (TW);</li>\n      <li>Yamadin (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21131924\"></a>Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. <i>Am J Gastroenterol</i>. 2010;105(12):2533-2549.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/21131924/pubmed\" target=\"_blank\" id=\"21131924\">21131924</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahmad S, &ldquo;Famotidine and Cardiac Arrhythmia,&rdquo; <i>DICP</i>, 1991, 25(3):315.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/2028638/pubmed\" target=\"_blank\" id=\"2028638\">2028638</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc. </i>2015;63(11):2227-2246. doi: 10.1002/ppul.23319<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Society of Anesthesiologists (ASA). Practice Guidelines for Obstetric Anesthesia: An Updated Report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia and the Society for Obstetric Anesthesia and Perinatology. <i>Anesthesiology</i>. 2016;124(2):270-300.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/26580836/pubmed\" target=\"_blank\" id=\"26580836\">26580836</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17413923\"></a>American Society of Anesthesiologists Task Force on Obstetric Anesthesia. Practice guidelines for obstetric anesthesia: an updated report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia. <i>Anesthesiology</i>. 2007;106(4):843-863. doi: 10.1097/01.anes.0000264744.63275.10<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/17413923/pubmed\" target=\"_blank\" id=\"17413923\">17413923</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, eds. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10690219\"></a>ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. <i>Am J Health Syst Pharm</i>. 1999;56(4):347-379.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/10690219/pubmed\" target=\"_blank\" id=\"10690219\">10690219</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7712759\"></a>Baghaie AA, Mojtahedzadeh M, Levine RL, Fromm RE Jr, Guntupalli KK, Opekun AR Jr. Comparison of the effect of intermittent administration and continuous infusion of famotidine on gastric pH in critically ill patients: results of a prospective, randomized, crossover study. <i>Crit Care Med</i>. 1995;23(4):687-691.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/7712759/pubmed\" target=\"_blank\" id=\"7712759\">7712759</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24766875\"></a>Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. <i>J Allergy Clin Immunol</i>. 2014;133(5):1270-1277.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/24766875/pubmed\" target=\"_blank\" id=\"24766875\">24766875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Broussard CN, Richter JE. Treating gastro-oesophageal reflux disease during pregnancy and lactation: what are the safest therapy options. <i>Drug Saf.</i> 1998;19(4):325-337.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/9804446/pubmed\" target=\"_blank\" id=\"9804446\">9804446</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16651285\"></a>Canani RB, Cirillo P, Roggero P, et al; Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP). Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. <i>Pediatrics</i>. 2006;117(5):e817-e820. doi: 10.1542/peds.2005-1655<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/16651285/pubmed\" target=\"_blank\" id=\"16651285\">16651285</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12635419\"></a>Cappell MS. Gastric and duodenal ulcers during pregnancy. <i>Gastroenterol Clin North Am</i>. 2003;32(1):263-308. doi: 10.1542/peds.2005-1655<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/12635419/pubmed\" target=\"_blank\" id=\"12635419\">12635419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Courtney, TP, Shaw RW, Cedar E, et al, &quot;Excretion of Famotidine in Breast Milk,&quot; Proceedings of the British Pharmacological Society, Clinical Pharmacology Section. Ireland, 6-8 July, 1988. Abstracts. <i>Br J Clin Pharmacol</i>, 1988;26(5):639P.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/3207568/pubmed\" target=\"_blank\" id=\"3207568\">3207568</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2895583\"></a>Dicke JM, Johnson RF, Henderson GI, Kuehl TJ, Schenker S. A comparative evaluation of the transport of H2-receptor antagonists by the human and baboon placenta. <i>Am J Med Sci</i>. 1988;295(3):198-206.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/2895583/pubmed\" target=\"_blank\" id=\"2895583\">2895583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fennerty MD, Higbee M. Drug Therapy of Gastrointestinal Disease. <i>Geriatric Pharmacology</i>, Bressler R and Katz MD, eds, New York, NY: McGraw-Hill; 1993, 585-608.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fish DN. Safety and Cost of Rapid I.V. Injection of Famotidine in Critically Ill Patients. <i>Am J Health Syst Pharm.</i> 1995;52(17):1889-1894.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/8528851/pubmed\" target=\"_blank\" id=\"8528851\">8528851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gottlieb S, Decktor DL, Eckert JM, et al. Efficacy and Tolerability of Famotidine in Preventing Heartburn and Related Symptoms of Upper Gastrointestinal Discomfort. <i>Am J Ther. </i>1995;2:314-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/11850669/pubmed\" target=\"_blank\" id=\"11850669\">11850669</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guillet R, Stoll BJ, Cotten CM, et al. Association of H2-Blocker Therapy and Higher Incidence of Necrotizing Enterocolitis in Very Low Birth Weight Infants. <i>Pediatrics.</i> 2006;117(2):137-142.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/16390920/pubmed\" target=\"_blank\" id=\"16390920\">16390920</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Inotsume N, Mishimura M, Nakano M, et al. Removal of Famotidine by Haemodialysis in Elderly Anuric Patients. <i>Eur J Clin Pharmacol.</i> 1990;38(3):313-314.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/2340853/pubmed\" target=\"_blank\" id=\"2340853\">2340853</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000; 343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    James L, Kearns GL. Pharmacokinetics and Pharmacodynamics of Famotidine in Paediatric Patients. <i>Clin Pharmacokinet.</i> 1996;31(2):103-110.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/8853932/pubmed\" target=\"_blank\" id=\"8853932\">8853932</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22183857\"></a>Kinoshita Y, Chiba T; FUTURE study group. Therapeutic effects of famotidine on chronic symptomatic gastritis: subgroup analysis from FUTURE study. <i>J Gastroenterol</i>. 2012;47(4):377-386.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/22183857/pubmed\" target=\"_blank\" id=\"22183857\">22183857</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. <i>JAMA</i>. 2013;310(22):2435-2422.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/24327038/pubmed\" target=\"_blank\" id=\"24327038\">24327038</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19240698\"></a>Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. <i>Am J Gastroenterol</i>. 2009;104(3):728-738.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/19240698/pubmed\" target=\"_blank\" id=\"19240698\">19240698</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20173630\"></a>Lin PC, Chang CH, Hsu PI, Tseng PL, Huang YB. The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis. <i>Crit Care Med</i>. 2010;38(4):1197-1205.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/20173630 /pubmed\" target=\"_blank\" id=\"20173630 \">20173630 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsy R, Freeman CD. Hemodynamic Effects of Intravenous Famotidine in Critically Ill Patients. <i>Pharmacotherapy. </i>1995;15(1):48-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/7739945/pubmed\" target=\"_blank\" id=\"7739945\">7739945</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12752346\"></a>Orenstein SR, Shalaby TM, Devandry SN, et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. <i>Aliment Pharmacol Ther</i>. 2003;17(9):1097-1107.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/12752346/pubmed\" target=\"_blank\" id=\"12752346\">12752346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pepcid (famotidine) [prescribing information]. Northbrook, IL: Marathon Pharmaceuticals; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poluzzi E, Raschi E, Moretti U, et al. Drug-Induced Torsades de Pointes: Data Mining of the Public Version of the FDA Adverse Event Reporting System (AERS). <i>Pharmacoepidemiol Drug Saf.</i> 2009;18(6):512-518.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/19358226/pubmed\" target=\"_blank\" id=\"19358226\">19358226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12635418\"></a>Richter JE. Gastroesophageal reflux disease during pregnancy. <i>Gastroenterol Clin North Am</i>. 2003;32(1):235-261.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/12635418/pubmed\" target=\"_blank\" id=\"12635418\">12635418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16225482\"></a>Richter JE. Review article: the management of heartburn in pregnancy. <i>Aliment Pharmacol Ther</i>. 2005;22(9):749-757. doi: 10.1111/j.1365-2036.2005.02654.x<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/16225482/pubmed\" target=\"_blank\" id=\"16225482\">16225482</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28101605\"></a>Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/28101605/pubmed\" target=\"_blank\" id=\"28101605\">28101605</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simon TJ, Berlin RG, Gardner AH, et al. Self-Directed Treatment of Intermittent Heartburn: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Evaluation of Antacid and Low Doses of an H<sub>2</sub>-Receptor Antagonist (Famotidine). <i>Am J Ther.</i> 1995;2:304-133.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/11850668/pubmed\" target=\"_blank\" id=\"11850668\">11850668</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Treem WR, Davis PM, Hyams JS. Suppression of Gastric Acid Secretion by Intravenous Administration of Famotidine in Children. <i>J Pediatr.</i> 1991;118(5):812-816.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/2019939/pubmed\" target=\"_blank\" id=\"2019939\">2019939</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van der Woude CJ, Metselaar HJ, Danese S. Management of gastrointestinal and liver diseases during pregnancy. <i>Gut</i>. 2014;63(6):1014-1023.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/24429582/pubmed\" target=\"_blank\" id=\"24429582\">24429582</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang X, Rytting E, Abdelrahman DR, Nanovskaya TN, Hankins GD, Ahmed MS. Quantitative determination of famotidine in human maternal plasma, umbilical cord plasma and urine using high-performance liquid chromatography-mass spectrometry. <i>Biomed Chromatogr</i>. 2013;27(7):866-873.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famotidine-drug-information/abstract-text/23401067/pubmed\" target=\"_blank\" id=\"23401067\">23401067</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang X, Zhan Y, Hankins GD et al. Pharmacokinetics of famotidine in pregnant women. <i>Am J Obstet Gynecol</i>. 2011;204:S72-S73.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8436 Version 244.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F169927\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F169928\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F169978\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F169931\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F169952\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F169932\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F169933\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F50049610\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F169901\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F169887\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F169904\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F169903\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725590\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7305905\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F169894\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F169907\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F169891\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299312\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F169896\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F169924\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F169898\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F169910\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F169911\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F50442698\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F169890\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F169906\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F169909\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F169913\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8436|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=famotidine-patient-drug-information\" class=\"drug drug_patient\">Famotidine: Patient drug information</a></li><li><a href=\"topic.htm?path=famotidine-pediatric-drug-information\" class=\"drug drug_pediatric\">Famotidine: Pediatric drug information</a></li></ul></div></div>","javascript":null}